3D Medicines Inc. (3D Medicines) has signed a supplementary agreement with Mega Link International Limited to prolong the maturity of its HK$50.00 million short-term note for an additional two years, pushing the due date from 14 August 2026 to 14 August 2028.

The extended instrument will now carry a fixed coupon of 9% per annum, up from the previous 7.5% rate applicable from August 2025 to August 2026. All accrued interest for the period 14 August 2023 to 14 August 2026 will be settled separately under agreed terms, while interest accruing from 15 August 2026 will be paid at maturity or upon any early redemption.

3D Medicines retains the right to demand early repayment by giving 15 days’ written notice, requiring Mega Link to repay the principal together with any accrued interest and other sums due. Standard default clauses allow 3D Medicines to declare all outstanding amounts immediately payable if Mega Link fails to meet its obligations or faces material solvency issues.

The board cited capital allocation optimisation and continued stable interest income as key motives for the extension. Proceeds will be channelled into research and development as well as general operating capital.

Under Hong Kong Listing Rules, the highest applicable percentage ratio related to the transaction exceeds 5% but is below 25%, classifying the deal as a discloseable transaction that requires public announcement but not shareholder approval. Directors affirmed that the terms are fair, conducted in the ordinary course of business, and in the best interests of shareholders.

Mega Link, incorporated in the British Virgin Islands, remains an independent third party with what 3D Medicines describes as sound financial standing and normal credit records.

Investors are advised to exercise caution when dealing in 3D Medicines’ securities pending further announcements.